Drug intelligence / Profile preview

F2i

Development stage: Preclinical
Lead developer: Invasight
Modality: Small Molecules

Overview

F2i is a **protein-protein interaction inhibitor drug** that was initially developed by Invasight AG. Its highest reported R&D status globally is **preclinical**, and detailed mechanism of action, molecular structure, and clinical use or indications are not publicly disclosed in primary medical or pharmacological databases. The modality is classified as a small molecule, but its biological target or disease indications have not been made public as of the latest search[7].

Other names: F2iF-2iF 2i

Beyond the preview

Go deeper on F2i.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F2i.

Explore the full profile